Unjha Formulations Ltd Stock Price Today (NSE: UNJHAFOR)
Fundamental Score
Unjha Formulations Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Unjha Formulations Ltd share price today is ₹20.29, down 1.10% on NSE/BSE as of 30 March 2026. Unjha Formulations Ltd (UNJHAFOR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.96 (Cr). The 52-week high for UNJHAFOR share price is ₹30.40 and the 52-week low is ₹19.00. At a P/E ratio of 10.74x, UNJHAFOR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.97% and a debt-to-equity ratio of 0.00.
Unjha Formulations Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Unjha Formulations Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Unjha Formulations Share Price: A Financial Analysis
The pharmaceutical industry, known for its intricate regulatory landscape and high R&D costs, often rewards companies with strong operational efficiencies and niche product portfolios. This analysis delves into the financial standing of Unjha Formulations Ltd, with a specific focus on its current valuation reflected in the Unjha Formulations share price of ₹22.95. This valuation occurs within the context of a competitive market where strategic positioning and financial prudence are critical for long-term success.
At a Price-to-Earnings (PE) ratio of 10.74, Unjha Formulations appears potentially undervalued compared to broader market averages. However, understanding the sustainability of this valuation requires a deeper dive. A crucial aspect is the company's Return on Capital Employed (ROCE) of 18.06%. This robust ROCE indicates efficient capital allocation, suggesting that the company generates significant profit from its investments. A high ROCE, maintained consistently, can contribute to a wider economic moat, making it harder for competitors to erode Unjha Formulations' market share. The peer comparison is essential: while we cannot definitively state superiority, one must ask if
Mankind Pharma Ltd's success might be attributed partly to superior management quality, and whether Unjha Formulations could benefit from similar improvements.Comparing Unjha Formulations with sector peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd is essential. While a detailed comparative analysis is beyond the scope of this summary, factors like revenue growth, debt levels, and cash flow generation relative to their respective valuations require careful consideration. Each company operates within specific therapeutic segments and geographies, influencing their individual risk profiles and growth trajectories.
It's important to note that this analysis is based on publicly available data and forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra. The analysis focuses on observational data and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Unjha Formulations Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of UNJHAFOR across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Excellent ROCE Performance (18.06%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 10.74 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (845.45%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Margin Pressure Concerns (2.84%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Negative Free Cash Flow (₹-0.16 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Unjha Formulations Ltd Financial Statements
Comprehensive financial data for Unjha Formulations Ltd including income statement, balance sheet and cash flow
About UNJHAFOR (Unjha Formulations Ltd)
Unjha Formulations Ltd is a distinguished player in the Indian pharmaceutical landscape, deeply rooted in the ancient wisdom of Ayurveda. The company is committed to crafting and d...istributing a range of traditional health and wellness products, primarily focused on leveraging the therapeutic potential of natural ingredients. With a strong emphasis on quality and efficacy, Unjha Formulations aims to provide accessible and reliable Ayurvedic solutions to meet the diverse healthcare needs of the Indian population. Their commitment to preserving and promoting this time-tested system of medicine is evident in their dedication to sourcing the finest raw materials and employing rigorous manufacturing processes. Unjha Formulations strives to bridge the gap between traditional healing practices and modern pharmaceutical standards. The company's flagship offerings revolve around the widely recognized benefits of Isabgol, a natural dietary fiber. Unjha Formulations innovatively presents Isabgol in palatable and convenient formats, catering to consumer preferences. They expertly blend the inherent benefits of this natural ingredient with appealing flavors, creating user-friendly products designed to support digestive health and overall well-being. This approach allows Unjha Formulations to effectively reach a broader audience, making the advantages of Ayurveda more accessible and enjoyable. Through a dedication to innovation and consumer-centric product development, they have solidified their position as a trusted provider of natural health solutions within the competitive Indian market. Furthermore, Unjha Formulations extends its reach beyond domestic borders through its export operations. By sharing the benefits of authentic Ayurvedic products with international markets, the company contributes to the growing global recognition and acceptance of traditional Indian medicine. This expansion strategy not only strengthens the company's financial standing but also showcases the rich heritage of Indian healthcare practices on a worldwide stage. From its base in Sidhpur, India, Unjha Formulations continues to build upon its legacy of providing quality Ayurvedic products, driven by a commitment to innovation, ethical practices, and the well-being of its consumers.
Company Details
Key Leadership
UNJHAFOR Share Price: Frequently Asked Questions
What is the current share price of Unjha Formulations Ltd (UNJHAFOR)?
As of 30 Mar 2026, 12:05 pm IST, Unjha Formulations Ltd share price is ₹20.29. The UNJHAFOR stock has a market capitalisation of ₹10.96 (Cr) on NSE/BSE.
Is UNJHAFOR share price Overvalued or Undervalued?
UNJHAFOR share price is currently trading at a P/E ratio of 10.74x, compared to the industry average of 31.77x. Based on this relative valuation, the Unjha Formulations Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of UNJHAFOR share price?
The 52-week high of UNJHAFOR share price is ₹30.40 and the 52-week low is ₹19.00. These values are updated daily from NSE/BSE price data.
What factors affect the Unjha Formulations Ltd share price?
Key factors influencing UNJHAFOR share price include quarterly earnings growth (Sales Growth: 13.49%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Unjha Formulations Ltd a good stock for long-term investment?
Unjha Formulations Ltd shows a 5-year Profit Growth of 5.75% and an ROE of 13.97%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in UNJHAFOR shares.
How does Unjha Formulations Ltd compare with its industry peers?
Unjha Formulations Ltd competes with major peers in the Pharmaceuticals. Investors should compare UNJHAFOR share price P/E of 10.74x and ROE of 13.97% against the industry averages to determine competitive standing.
What is the P/E ratio of UNJHAFOR and what does it mean?
UNJHAFOR share price has a P/E ratio of 10.74x compared to the industry average of 31.77x. Investors pay ₹11 for every ₹1 of annual earnings.
How is UNJHAFOR performing according to Bull Run's analysis?
UNJHAFOR has a Bull Run fundamental score of 38.8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does UNJHAFOR belong to?
UNJHAFOR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Unjha Formulations Ltd share price.
What is Return on Equity (ROE) and why is it important for UNJHAFOR?
UNJHAFOR has an ROE of 13.97%, which shows decent profitability but room for improvement. ROE measures how efficiently Unjha Formulations Ltd generates profits from shareholders capital.
How is UNJHAFOR debt-to-equity ratio and what does it indicate?
UNJHAFOR has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is UNJHAFOR dividend yield and is it a good dividend stock?
UNJHAFOR offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Unjha Formulations Ltd shares.
How has UNJHAFOR share price grown over the past 5 years?
UNJHAFOR has achieved 5-year growth rates of: Sales Growth 5.53%, Profit Growth 5.75%, and EPS Growth 5.75%.
What is the promoter holding in UNJHAFOR and why does it matter?
Promoters hold 36.92% of UNJHAFOR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Unjha Formulations Ltd.
What is UNJHAFOR market capitalisation category?
UNJHAFOR has a market capitalisation of ₹11 crores, placing it in the Small-cap category.
How volatile is UNJHAFOR stock?
UNJHAFOR has a beta of N/A. A beta > 1 suggests the Unjha Formulations Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is UNJHAFOR operating profit margin trend?
UNJHAFOR has a 5-year average Operating Profit Margin (OPM) of 2.84%, indicating the company's operational efficiency.
How is UNJHAFOR quarterly performance?
Recent quarterly performance shows Unjha Formulations Ltd YoY Sales Growth of 13.49% and YoY Profit Growth of 845.45%.
What is the institutional holding pattern in UNJHAFOR?
UNJHAFOR has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Unjha Formulations Ltd stock.